Mark Leick, MD, discusses the challenges and limitations associated with the use of CAR T-cell therapy across hematologic malignancies, highlighting how ongoing research may potentially ameliorate present unmet needs.
Mark Leick, MD, discusses the varying role of CAR T-cell therapy across various hematologic malignancies, elaborating on the cause of its effectiveness in these disease spaces.
Several biotechs in Mass. are seeking to elbow their way into the lucrative market, which is currently dominated by Denmark’s Novo Nordisk, which makes Wegovy and Ozempic, and Eli Lilly, which produces Mounjaro.
Researchers at Tampere University s Faculty of Medicine and Health Technology in Finland, the Massachusetts General Research Institute, and the Harvard Stem Cell Institute discovered a new combination.